Free tool
FAERS Monitor: Nesacaine-Mpf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009435 or its brand name (Nesacaine-Mpf, Chloroprocaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
34
Serious
20
59% of reports
Hospitalization
9
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective7
- hypotension3
- product label confusion3
- anaesthetic complication2
- areflexia2
- arthralgia2
- back pain2
- bradycardia2
- drug dose omission2
- dyspnoea2
- headache2
- hypoaesthesia2
- intentional product use issue2
- intervertebral disc protrusion2
- medication error2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,125 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| areflexia | 2 | 463.8 | 120.8 | 519 |
| anaesthetic complication | 2 | 461.1 | 120.1 | 515 |
| product label confusionSignal | 3 | 318.6 | 108.1 | 659 |
| intervertebral disc protrusion | 2 | 56.6 | 14.8 | 61 |
| bradycardia | 2 | 23.3 | 6.1 | 23 |
| medication error | 2 | 22.3 | 5.8 | 22 |
| intentional product use issue | 2 | 14.1 | 3.7 | 13 |
| hypotensionSignal | 3 | 9.3 | 3.1 | 15 |
| hypoaesthesia | 2 | 8.3 | 2.2 | 7 |
| drug dose omission | 2 | 7.5 | 2.0 | 6 |
| back pain | 2 | 5.3 | 1.4 | 3 |
| drug ineffectiveSignal | 7 | 3.3 | 1.7 | 10 |
| arthralgia | 2 | 3.0 | 0.8 | 1 |
| dyspnoea | 2 | 2.2 | 0.6 | 0 |
| headache | 2 | 2.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.